FI2140867T4 - Farmaseuttinen koostumus - Google Patents
Farmaseuttinen koostumus Download PDFInfo
- Publication number
- FI2140867T4 FI2140867T4 FIEP08720658.7T FI08720658T FI2140867T4 FI 2140867 T4 FI2140867 T4 FI 2140867T4 FI 08720658 T FI08720658 T FI 08720658T FI 2140867 T4 FI2140867 T4 FI 2140867T4
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- composition according
- methyl
- coating agent
- tetrahydrothiazolo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 11
- 239000011248 coating agent Substances 0.000 claims 4
- -1 5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl Chemical group 0.000 claims 3
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007087327 | 2007-03-29 | ||
| PCT/JP2008/000791 WO2008129846A1 (ja) | 2007-03-29 | 2008-03-28 | 医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2140867T4 true FI2140867T4 (fi) | 2023-09-14 |
Family
ID=39875378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP08720658.7T FI2140867T4 (fi) | 2007-03-29 | 2008-03-28 | Farmaseuttinen koostumus |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20100081685A1 (enExample) |
| EP (1) | EP2140867B2 (enExample) |
| JP (2) | JP4463875B2 (enExample) |
| KR (1) | KR101424843B1 (enExample) |
| CN (2) | CN101652139A (enExample) |
| AU (1) | AU2008241982B2 (enExample) |
| BR (1) | BRPI0809205B8 (enExample) |
| CA (1) | CA2680039C (enExample) |
| CO (1) | CO6220955A2 (enExample) |
| CY (1) | CY1119377T1 (enExample) |
| DK (1) | DK2140867T4 (enExample) |
| ES (1) | ES2644803T5 (enExample) |
| FI (1) | FI2140867T4 (enExample) |
| HR (1) | HRP20171384T4 (enExample) |
| HU (2) | HUE035990T2 (enExample) |
| IL (2) | IL200790A (enExample) |
| LT (2) | LT2140867T (enExample) |
| MX (2) | MX2009010474A (enExample) |
| MY (1) | MY149356A (enExample) |
| NO (1) | NO20093008L (enExample) |
| NZ (2) | NZ597109A (enExample) |
| PL (1) | PL2140867T5 (enExample) |
| PT (1) | PT2140867T (enExample) |
| SG (1) | SG179497A1 (enExample) |
| SI (1) | SI2140867T2 (enExample) |
| TW (1) | TWI409064B (enExample) |
| WO (1) | WO2008129846A1 (enExample) |
| ZA (2) | ZA200906182B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2644803T5 (es) | 2007-03-29 | 2024-02-26 | Daiichi Sankyo Co Ltd | Composición farmacéutica |
| CN102256984B (zh) | 2008-12-17 | 2014-09-03 | 第一三共株式会社 | 制备二胺衍生物的方法 |
| EP2374456B1 (en) * | 2008-12-19 | 2016-08-03 | Daiichi Sankyo Company, Limited | Edoxaban dosage regime |
| JPWO2010082531A1 (ja) | 2009-01-13 | 2012-07-05 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| EP2407457B1 (en) | 2009-03-10 | 2015-04-22 | Daiichi Sankyo Company, Limited | Process for producing diamine derivative |
| JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
| CA2760073A1 (en) * | 2009-04-30 | 2010-11-04 | Takeda Pharmaceutical Company Limited | Solid preparation |
| KR20120037396A (ko) * | 2009-06-18 | 2012-04-19 | 다이이찌 산쿄 가부시키가이샤 | 용출성이 개선된 의약 조성물 |
| TW201132646A (en) * | 2010-02-22 | 2011-10-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
| ES2706880T3 (es) * | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
| TW201200165A (en) * | 2010-02-22 | 2012-01-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
| KR101792299B1 (ko) * | 2010-03-19 | 2017-10-31 | 다이이찌 산쿄 가부시키가이샤 | 항응고제의 용출 개선 방법 |
| CN102791719B (zh) | 2010-03-19 | 2015-07-29 | 第一三共株式会社 | 二胺衍生物的晶体及其制备方法 |
| CN103080078B (zh) * | 2010-07-02 | 2015-02-11 | 第一三共株式会社 | 光学活性二胺衍生物盐的制备方法 |
| KR101940840B1 (ko) * | 2011-08-10 | 2019-01-21 | 다이이찌 산쿄 가부시키가이샤 | 디아민 유도체 함유 의약 조성물 |
| WO2013026553A1 (en) | 2011-08-22 | 2013-02-28 | Ratiopharm Gmbh | Composition comprising edoxaban |
| RU2665372C2 (ru) | 2012-09-03 | 2018-08-29 | Дайити Санкио Компани, Лимитед | Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона |
| JP6227352B2 (ja) * | 2012-09-27 | 2017-11-08 | 株式会社三和化学研究所 | アナグリプチン又はその塩を含有する固形製剤 |
| EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE |
| TW201521794A (zh) * | 2013-11-12 | 2015-06-16 | Daiichi Sankyo Co Ltd | 錠劑 |
| WO2015129603A1 (ja) * | 2014-02-25 | 2015-09-03 | 第一三共株式会社 | 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤の高純度結晶 |
| JPWO2016104678A1 (ja) * | 2014-12-26 | 2017-10-12 | 第一三共株式会社 | 線溶を促進するための医薬組成物 |
| WO2017107857A1 (zh) * | 2015-12-24 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 一种含有二胺衍生物或其盐的固体药物组合物 |
| JP6738477B2 (ja) * | 2016-03-16 | 2020-08-12 | ゴールデン オメガ ノルウェー アーエス | ω−３脂肪酸誘導体を含む粉末及び錠剤、ならびにその製造方法 |
| JP6673798B2 (ja) * | 2016-10-12 | 2020-03-25 | 日本化薬株式会社 | カペシタビンを有効成分とするフィルムコート医薬製剤 |
| TWI812602B (zh) | 2016-12-01 | 2023-08-21 | 日商第一三共股份有限公司 | 含二胺衍生物之口腔崩散錠及其製造方法 |
| TWI826474B (zh) * | 2018-06-27 | 2023-12-21 | 日商第一三共股份有限公司 | 包含二胺衍生物之顆粒劑、以及其用途及製造方法 |
| KR102222774B1 (ko) * | 2018-07-27 | 2021-03-04 | 보령제약 주식회사 | 에독사반을 포함하는 약학적 제제 및 이의 제조방법 |
| KR20200079957A (ko) | 2018-12-26 | 2020-07-06 | 한국콜마주식회사 | 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법 |
| KR102514961B1 (ko) | 2019-03-05 | 2023-03-28 | 주식회사 파마코스텍 | 에독사반 벤젠술폰산염 1 수화물 결정형 및 그 제조방법 |
| EP3744320A1 (en) | 2019-05-29 | 2020-12-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising edoxaban |
| KR20210048632A (ko) | 2019-10-23 | 2021-05-04 | 한미약품 주식회사 | 에독사반 유리 염기 함유 제약 조성물 |
| KR102333564B1 (ko) | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 |
| KR102090912B1 (ko) | 2019-12-18 | 2020-03-18 | 유니셀랩 주식회사 | 신규한 결정형 형태의 에독사반 및 이의 제조방법 |
| EP3838267A1 (en) | 2019-12-19 | 2021-06-23 | Biohorm, S.L. | Edoxaban tablets |
| KR102513519B1 (ko) | 2020-06-08 | 2023-03-23 | 주식회사 파마코스텍 | 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법 |
| KR102222784B1 (ko) | 2020-09-17 | 2021-03-04 | 유니셀랩 주식회사 | 신규한 에독사반 헤미에틸렌다이설퍼닉산 염 일수화물 |
| WO2022129535A1 (en) | 2020-12-18 | 2022-06-23 | Krka, D.D., Novo Mesto | Edoxaban formulation containing no sugar alcohols |
| JP2022113667A (ja) * | 2021-01-25 | 2022-08-04 | 全星薬品工業株式会社 | エドキサバン含有医薬組成物 |
| JP2023056113A (ja) * | 2021-10-07 | 2023-04-19 | 日医工株式会社 | エドキサバン含有医薬組成物 |
| KR102518204B1 (ko) | 2022-02-18 | 2023-04-05 | 주식회사 엔비피헬스케어 | 신규한 에독사반 프로필렌글리콜 용매화물 |
| WO2024121413A1 (en) | 2022-12-09 | 2024-06-13 | Synthon B.V. | Formulation comprising edoxaban and preparation thereof |
| JP7352248B1 (ja) * | 2023-03-27 | 2023-09-28 | 学校法人藤田学園 | 抗がん剤 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361545A (en) * | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| JP2814513B2 (ja) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | 溶出性の改良された製剤組成物 |
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| US5149855A (en) | 1989-12-26 | 1992-09-22 | Mitsubishi Rayon Co., Ltd. | Process for racemizing optically active carboxylic acid esters |
| US5055600A (en) | 1990-04-24 | 1991-10-08 | Rockwell International Corporation | Glycidyl azide polymer (gap) synthesis by molten salt method |
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| US5506248A (en) | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US5677469A (en) | 1995-05-18 | 1997-10-14 | Sepracor, Inc. | Process for resolving chiral acids with 1-aminoindan-2-ols |
| JPH09309829A (ja) * | 1996-05-22 | 1997-12-02 | Taiyo Yakuhin Kogyo Kk | ニトレンジピン含有経口投与製剤およびその製造法 |
| EP0839526A3 (en) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
| JPH11180899A (ja) | 1997-12-15 | 1999-07-06 | Mitsui Chem Inc | 活性メチレンアルキル化化合物の製造法 |
| JP3680203B2 (ja) | 1999-06-01 | 2005-08-10 | 東洋化成工業株式会社 | ４−アセチルアミノベンゼンスルホニルアジドの製造方法 |
| JP4044709B2 (ja) * | 1999-11-19 | 2008-02-06 | 信越化学工業株式会社 | 水系フィルムコーティング剤及び経口固形製剤 |
| JP2001151724A (ja) | 1999-11-19 | 2001-06-05 | Kuraray Co Ltd | 光学活性な２，２，４−トリメチル−３−シクロヘキセンカルボン酸の製造方法 |
| TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
| BR0114896A (pt) | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| DE10106971A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Arzneimittelformulierung die einen muskarinischen Agonisten enthält |
| US20020160048A1 (en) * | 2001-02-15 | 2002-10-31 | Karoline Bechtold-Peters | Medical formulation containing a muscarinic agonist |
| RU2319699C2 (ru) | 2001-06-20 | 2008-03-20 | Дайити Санкио Компани, Лимитед | Производные диаминов |
| KR100908418B1 (ko) * | 2001-06-20 | 2009-07-21 | 액티버스 파마 컴퍼니 리미티드 | 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법 |
| JP3939601B2 (ja) * | 2001-06-20 | 2007-07-04 | 株式会社アクティバスファーマ | キノリノン誘導体医薬組成物及びその製造方法 |
| WO2003000657A1 (en) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| CN100545160C (zh) | 2001-08-09 | 2009-09-30 | 第一制药株式会社 | 二胺衍生物 |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| TW200306868A (en) * | 2002-05-22 | 2003-12-01 | Shionogi & Co | Composition of hardly soluble medicine with improved solubility |
| MXPA05006989A (es) | 2002-12-25 | 2005-09-22 | Daiichi Seiyaku Co | Derivados de diamina. |
| DE202004021680U1 (de) * | 2003-04-08 | 2010-04-22 | Novartis Ag | Feste pharmazeutische Zusammensetzung |
| JP3786287B2 (ja) * | 2003-06-17 | 2006-06-14 | 協和醗酵工業株式会社 | 塩酸ベニジピン含有医薬組成物 |
| JP4606258B2 (ja) * | 2003-06-17 | 2011-01-05 | 協和発酵キリン株式会社 | 塩酸ベニジピン含有医薬組成物 |
| CA2773066A1 (en) | 2003-11-12 | 2005-05-26 | Daiichi Sankyo Company, Limited | Process for producing thiazole derivative |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| US8686189B2 (en) | 2005-09-16 | 2014-04-01 | Daiichi Sankyo Company, Limited | Optically active diamine derivative and process for producing the same |
| JP4703333B2 (ja) | 2005-09-26 | 2011-06-15 | エヌ・ティ・ティ・ソフトウェア株式会社 | 電子メール処理プログラム |
| ES2644803T5 (es) | 2007-03-29 | 2024-02-26 | Daiichi Sankyo Co Ltd | Composición farmacéutica |
| TW200909437A (en) | 2007-06-21 | 2009-03-01 | Daiichi Sankyo Co Ltd | Process for the preparation of diamine-derivatives |
| CN102317248A (zh) | 2008-12-12 | 2012-01-11 | 第一三共株式会社 | 光学活性羧酸的生产方法 |
| CN102256984B (zh) | 2008-12-17 | 2014-09-03 | 第一三共株式会社 | 制备二胺衍生物的方法 |
| EP2374456B1 (en) | 2008-12-19 | 2016-08-03 | Daiichi Sankyo Company, Limited | Edoxaban dosage regime |
| JPWO2010082531A1 (ja) | 2009-01-13 | 2012-07-05 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| EP2407457B1 (en) | 2009-03-10 | 2015-04-22 | Daiichi Sankyo Company, Limited | Process for producing diamine derivative |
| JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
| WO2010131663A1 (ja) | 2009-05-15 | 2010-11-18 | 第一三共株式会社 | オキサミド誘導体 |
| KR20120037396A (ko) | 2009-06-18 | 2012-04-19 | 다이이찌 산쿄 가부시키가이샤 | 용출성이 개선된 의약 조성물 |
| JP2011051672A (ja) | 2009-08-31 | 2011-03-17 | Ihi Corp | ラック棚及びラック棚の組立て方法 |
| CN102791719B (zh) | 2010-03-19 | 2015-07-29 | 第一三共株式会社 | 二胺衍生物的晶体及其制备方法 |
| US20130158069A1 (en) | 2011-12-14 | 2013-06-20 | Daiichi Sankyo Company, Limited | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment |
-
2008
- 2008-03-28 ES ES08720658T patent/ES2644803T5/es active Active
- 2008-03-28 LT LTEP08720658.7T patent/LT2140867T/lt unknown
- 2008-03-28 MX MX2009010474A patent/MX2009010474A/es active IP Right Grant
- 2008-03-28 MY MYPI20093689 patent/MY149356A/en unknown
- 2008-03-28 FI FIEP08720658.7T patent/FI2140867T4/fi active
- 2008-03-28 DK DK08720658.7T patent/DK2140867T4/da active
- 2008-03-28 BR BRPI0809205A patent/BRPI0809205B8/pt active IP Right Grant
- 2008-03-28 CA CA2680039A patent/CA2680039C/en active Active
- 2008-03-28 CN CN200880010935A patent/CN101652139A/zh active Pending
- 2008-03-28 CN CN201410468293.6A patent/CN104324015B/zh active Active
- 2008-03-28 HR HRP20171384TT patent/HRP20171384T4/hr unknown
- 2008-03-28 HU HUE08720658A patent/HUE035990T2/en unknown
- 2008-03-28 PL PL08720658.7T patent/PL2140867T5/pl unknown
- 2008-03-28 SG SG2012018826A patent/SG179497A1/en unknown
- 2008-03-28 KR KR1020097019320A patent/KR101424843B1/ko active Active
- 2008-03-28 NZ NZ59710908A patent/NZ597109A/xx unknown
- 2008-03-28 SI SI200831863T patent/SI2140867T2/sl unknown
- 2008-03-28 NZ NZ579725A patent/NZ579725A/en unknown
- 2008-03-28 PT PT87206587T patent/PT2140867T/pt unknown
- 2008-03-28 TW TW97111503A patent/TWI409064B/zh active
- 2008-03-28 WO PCT/JP2008/000791 patent/WO2008129846A1/ja not_active Ceased
- 2008-03-28 EP EP08720658.7A patent/EP2140867B2/en active Active
- 2008-03-28 JP JP2009510780A patent/JP4463875B2/ja active Active
- 2008-03-28 AU AU2008241982A patent/AU2008241982B2/en active Active
- 2008-03-28 MX MX2011010260A patent/MX351987B/es unknown
-
2009
- 2009-09-07 ZA ZA2009/06182A patent/ZA200906182B/en unknown
- 2009-09-07 IL IL200790A patent/IL200790A/en not_active IP Right Cessation
- 2009-09-16 NO NO20093008A patent/NO20093008L/no unknown
- 2009-09-28 CO CO09106060A patent/CO6220955A2/es not_active Application Discontinuation
- 2009-09-29 US US12/569,057 patent/US20100081685A1/en not_active Abandoned
-
2010
- 2010-01-18 JP JP2010007969A patent/JP2010090168A/ja active Pending
- 2010-08-18 ZA ZA2010/05906A patent/ZA201005906B/en unknown
-
2012
- 2012-05-16 IL IL219829A patent/IL219829A0/en unknown
-
2013
- 2013-08-16 US US13/968,776 patent/US9149532B2/en active Active
-
2015
- 2015-08-12 US US14/825,036 patent/US9707296B2/en active Active
-
2017
- 2017-09-20 CY CY20171100990T patent/CY1119377T1/el unknown
-
2018
- 2018-01-25 LT LTPA2018005C patent/LTC2140867I2/lt unknown
- 2018-02-12 HU HUS1800007C patent/HUS1800007I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171384T1 (hr) | Farmaceutski pripravak | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| FI2049506T4 (fi) | Lääkkeellisten aineiden farmakokineettisten ominaisuuksien modulaattorit | |
| BRPI0513841A (pt) | composto, composição farmacêutica, e uso do composto | |
| WO2008133896A3 (en) | Dual-acting antihypertensive agents | |
| ME02558B (me) | Inhibitori replikacije virusa gripa | |
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| WO2008097459A3 (en) | Dual-acting antihypertensive agents | |
| WO2010011821A3 (en) | Dual-acting antihypertensive agents | |
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| BRPI0609515A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| EA200701745A1 (ru) | Циклопропанкарбоксамидные производные | |
| WO2009135179A3 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| JP2010504343A5 (enExample) | ||
| JP2010090168A5 (enExample) | ||
| RU2009126767A (ru) | Производное 1-фенил-1-тио-d-глюцитола | |
| WO2007126900A3 (en) | Antifungal agents | |
| RU2012101649A (ru) | Фармацевтическая композиция, обладающая улучшенной растворимостью | |
| WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
| WO2008000421A3 (en) | Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors | |
| EP2238105A4 (en) | NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| WO2006051314A8 (en) | Guanidine derivatives as inhibitors of ddah | |
| WO2009038411A3 (en) | Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety | |
| JP2026503816A (ja) | ニトロソアミン阻害剤としてのアルキル ３，４，５－トリヒドロキシベンゾエートを含有する固形経口医薬組成物 |